Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ernexa Therapeutics (ERNA) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to $8.2 million.

  • Ernexa Therapeutics' Shares Outstanding (Weighted Average) rose 217867.04% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year increase of 217867.04%. This contributed to the annual value of $13.6 million for FY2024, which is 15681.22% up from last year.
  • As of Q3 2025, Ernexa Therapeutics' Shares Outstanding (Weighted Average) stood at $8.2 million, which was up 217867.04% from $5.2 million recorded in Q2 2025.
  • In the past 5 years, Ernexa Therapeutics' Shares Outstanding (Weighted Average) registered a high of $53.4 million during Q1 2025, and its lowest value of $27799.0 during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $5.2 million (2023), whereas its average is $9.1 million.
  • As far as peak fluctuations go, Ernexa Therapeutics' Shares Outstanding (Weighted Average) tumbled by 9984.12% in 2021, and later soared by 954423.18% in 2022.
  • Over the past 5 years, Ernexa Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $2.5 million in 2021, then grew by 20.74% to $3.1 million in 2022, then soared by 74.17% to $5.3 million in 2023, then skyrocketed by 156.81% to $13.6 million in 2024, then tumbled by 39.72% to $8.2 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $8.2 million for Q3 2025, versus $5.2 million for Q2 2025 and $53.4 million for Q1 2025.